# Drug Target Validation Framework for Biologics

## Overview
Target validation is the process of establishing that modulating a specific molecular target will produce a therapeutic benefit. The strength of validation directly predicts clinical success probability.

## Tier 1: Genetic Evidence (Strongest)
Human genetic evidence is the gold standard for target validation.

- **Mendelian randomization**: Natural genetic variants that alter target expression/function provide causal evidence
- **Loss-of-function variants**: Rare LOF variants in humans that phenocopy the desired therapeutic effect are highly predictive
- **GWAS associations**: Genome-wide significant associations between target locus SNPs and disease phenotype
- **Gain-of-function mutations**: Activating mutations that cause disease suggest inhibiting the target may be therapeutic
- **Somatic mutations in cancer**: Recurrent mutations, amplifications, or fusions identify oncogenic drivers

Targets with human genetic validation have approximately 2x higher clinical success rates.

## Tier 2: Disease Biology Evidence
- Target is expressed in disease-relevant tissue/cell type but not widely in normal tissue
- Target expression correlates with disease severity or patient outcomes
- Target pathway is a known disease mechanism (e.g., cytokine in inflammatory disease)
- Biomarker data shows target is active/elevated in disease state

## Tier 3: Functional Validation
- Knockdown, knockout, or pharmacological inhibition in disease-relevant cell models reduces disease phenotype
- Animal model data (knockout mice, transgenic overexpression, pharmacological studies)
- Ex vivo studies in patient-derived tissue or primary cells

## Tier 4: Indirect/Circumstantial Evidence
- Target is in a validated disease pathway (downstream of a validated target)
- Analogy to validated targets in related biology
- Computational predictions from multi-omics datasets

## Red Flags
- Target is essential for normal cell function (high fitness score in DepMap for normal cells)
- Broad expression across many normal tissues → toxicity risk
- Negative results in animal models with good disease relevance
- Failed trials with same mechanism (unless clear differentiation reason)
- Conflicting data across studies

## Safety Considerations for Biologics
- On-target toxicity: What happens when you fully block this target in healthy tissue?
- Immunogenicity risk of the biologic format
- Cytokine release syndrome risk (especially for T-cell engaging formats)
- Long-term immunosuppression if target is immune regulatory
